We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDPH
RNS Number : 2354K
Dechra Pharmaceuticals PLC
19 September 2016
The announcement below replaces an announcement released in error on 15 September 2016 under RNS number 9802J. That announcement should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. In addition, the number of awards for Ian Page have been amended from 73,667 to 73,260 as below.
19 September 2016
Dechra Pharmaceuticals PLC
(the Company)
Director Shareholding
The Company announces that on 19 September 2016 the following Directors were granted awards over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the Plan):
Name of individual Director Type of award Number of shares subject to award -------------------- ---------- ---------------- ---------------- LTIP Award - nil cost Ian Page Director option 73,260 -------------------- ---------- ---------------- ---------------- LTIP Award - Conditional Tony Griffin Director award 20,858 -------------------- ---------- ---------------- ----------------
The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance measure. If the ROCE performance condition is not met, then the LTIP options will lapse in full.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") --- ------------------------------------------------------------------ a) Name Ian Page --- ----------------------------- ----------------------------------- 2. Reason for the notification --- ------------------------------------------------------------------ a) Position/status Director --- ----------------------------- ----------------------------------- b) Initial notification/ Amendment amendment Previous notification reference number: 3684. The notification should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. In addition, the number of awards have been amended from 73,667 to 73,260 as below. --- ----------------------------- ----------------------------------- 3. Details of the Issuer --- ------------------------------------------------------------------ a) Name Dechra Pharmaceuticals PLC --- ----------------------------- ----------------------------------- b) LEI code N/A --- ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------------ a) Description Ordinary Shares of 1 pence of the financial each instrument ISIN: GB0009633180 Identification code --- ----------------------------- ----------------------------------- b) Nature of Grant of nil cost options the transaction under the Company's Long Term Incentive Plan --- ----------------------------- ----------------------------------- c) Price(s) and Price(s) Volume(s) volumes(s) Nil cost 73,260 --- ----------------------------- ----------------- ---------------- d) Aggregated N/A information * Aggregate volume * Price --- ----------------------------- ----------------------------------- e) Date of the 2016.09.19 transaction --- ----------------------------- ----------------------------------- f) Place of the Outside a trading venue transaction --- ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") --- ------------------------------------------------------------------ a) Name Tony Griffin --- ----------------------------- ----------------------------------- 2. Reason for the notification --- ------------------------------------------------------------------ a) Position/status Director --- ----------------------------- ----------------------------------- b) Initial notification/ Amendment amendment Previous notification reference number: 3687. The notification should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. --- ----------------------------- ----------------------------------- 3. Details of the Issuer --- ------------------------------------------------------------------ a) Name Dechra Pharmaceuticals PLC --- ----------------------------- ----------------------------------- b) LEI code N/A --- ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------------ a) Description Ordinary Shares of 1 pence of the financial each instrument ISIN: GB009633180 Identification code --- ----------------------------- ----------------------------------- b) Nature of Grant of a conditional award the transaction under the Company's Long Term Incentive Plan --- ----------------------------- ----------------------------------- c) Price(s) and Price(s) Volume(s) volumes(s) Nil cost 20,858 --- ----------------------------- ----------------- ---------------- d) Aggregated N/A information * Aggregate volume * Price --- ----------------------------- ----------------------------------- e) Date of the 2016.09.19 transaction --- ----------------------------- ----------------------------------- f) Place of the Outside a trading venue transaction --- ----------------------------- -----------------------------------
For further information, please contact:
Suzana Cross, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKCDKQBKDFCD
(END) Dow Jones Newswires
September 19, 2016 10:10 ET (14:10 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions